Petros Grivas, MD, PhD, Seattle Cancer Care Alliance, Seattle, WA, touches on the role of genomic testing in patients with urothelial cancer, highlighting the importance of identifying targetable mutations. In addition, Dr Grivas reports the high incidence of somatic alterations seen in urothelial carcinoma which have implications for patients as well as their families. This interview took place at the PROSCA/BLADDR 2021 congress.